Get the Stockscreener App
3.74
2.48%
0.09
X 4 Pharmaceuticals Inc stock is traded at $3.74, with a volume of 59,305.
It is up +2.48% in the last 24 hours and up +19.13% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.65
Open:
$3.71
24h Volume:
59,305
Relative Volume:
0.06
Market Cap:
$83.74M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.3892
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
+0.28%
1M Performance:
+19.13%
6M Performance:
+38.03%
1Y Performance:
-63.37%
1-Day Range:
$3.6701
$3.82
1-Week Range:
$3.50
$3.86
52-Week Range:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.73 | 319.14M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.77 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
735.87 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.27 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
929.89 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.61 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Is X4 Pharmaceuticals Inc. stock positioned for digital transformationQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Why X4 Pharmaceuticals Inc. (48Q0) stock remains top ratedJuly 2025 Earnings & Consistent Growth Equity Picks - newser.com
Will X4 Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - Setenews
How to build a dashboard for X4 Pharmaceuticals Inc. stockWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
What moving averages say about X4 Pharmaceuticals Inc.2025 Year in Review & Momentum Based Trading Ideas - newser.com
Why X4 Pharmaceuticals Inc. stock could benefit from AI revolutionPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
How strong is X4 Pharmaceuticals Inc. stock revenue growthJuly 2025 Decliners & Reliable Volume Spike Trade Alerts - newser.com
Is X4 Pharmaceuticals Inc. stock a buy in volatile marketsDollar Strength & High Yield Equity Trading Tips - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from AI adoptionRisk Management & Technical Pattern Based Buy Signals - newser.com
Will X4 Pharmaceuticals Inc. stock benefit from commodity pricesChart Signals & Community Trade Idea Sharing Platform - newser.com
Fierce Biotech Layoff Tracker 2025: Kite cuts roles; Ventus undertakes 2nd layoff round this year - Fierce Biotech
Using economic indicators to assess X4 Pharmaceuticals Inc. potential2025 Price Targets & Advanced Swing Trade Entry Alerts - newser.com
Is X4 Pharmaceuticals Inc. (48Q0) stock a fit for income portfoliosFed Meeting & Comprehensive Market Scan Reports - newser.com
What analysts say about X4 Pharmaceuticals Inc 48Q0 stockPrice Action Trading & Backtest Your Strategy Before You Risk Money - earlytimes.in
Take off with X4 Pharmaceuticals Inc (XFOR): Get ready for trading - setenews.com
Goldman says healthcare is ripe for stock picking; here's some they like (XLV:NYSEARCA) - Seeking Alpha
What recovery options are there for X4 Pharmaceuticals Inc.Trade Exit Report & Low Drawdown Momentum Trade Ideas - newser.com
How dovish Fed policy supports X4 Pharmaceuticals Inc. (48Q0) stock2025 Market Outlook & Free Risk Controlled Daily Trade Plans - newser.com
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in X4 Pharmac - GuruFocus
What candlestick patterns are forming on X4 Pharmaceuticals Inc.Portfolio Profit Report & Weekly Stock Performance Updates - newser.com
X4 Pharmaceuticals: Q3 Earnings Snapshot - ctinsider.com
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
0.31%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):